parasitic%20infections
PARASITIC INFECTIONS
Gastrointestinal parasitic infection symptoms include abdominal pain, diarrhea, dysentery, flatulence, malabsorption and symptoms of biliary obstruction.
It can be caused by protozoan parasites and helminths.
Host susceptibility factors in gastrointestinal parasitic infections are nutritional status, intercurrent disease, pregnancy, immunosuppressive drugs and presence of a malignancy.
Knowledge of the geographic distribution of parasites is helpful in the diagnosis of patients.

Diagnosis

  • Attempt to elicit a history of possible exposure, especially for helminthic infections, eg eating undercooked meat, source of drinking water, swimming in fresh water where certain parasites may be endemic
  • Knowledge of the geographic distribution of parasites is helpful in the diagnosis of patients

Physical Examination

  • Pallor
  • Hepatomegaly
  • Ascites
  • Ileus
  • Rectal prolapse

Laboratory Tests

Microscopic Exam of Stools

  • Fundamental to the diagnosis of all GI infections
    • A minimum of 3 stool specimens, examined by trained personnel using a concentration & a permanent stain technique, should be used
    • The stool exam is used to detect protozoan cysts & trophozoites, helminth ova, proglottids, larvae or adult worms
    • A fecal sample must be mixed well before examination because eggs are never uniformly distributed in feces

Other Laboratory Tests

  • The following are other tests that may be used to document a GI parasitic infection:
    • Duodenal aspirate
    • Biopsy
    • String capsule test
    • Immunofluorescent antibody test
    • Enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR)
    • Cellophane tape test
    • Barium studies
  • Anemia & eosinophilia may be seen on the complete blood count (CBC)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
6 days ago
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
4 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.